MEDICAL DEVICES, TECHNOLOGIES, EQUIPMENT, SUPPLIES
1 min.Read

NIOX® Group Celebrates 25 Years of Innovation in FeNO Testing for Asthma

NIOX® Group (NIOX®) proudly announces the celebration of the 25th anniversary of its cutting-edge asthma diagnosis and management technology. Since its foundation, the company has worked to help improve asthma care with its ground-breaking FeNO testing devices. With almost 50 million tests performed worldwide, NIOX® continues to lead the development of FeNO for patient care.

NIOX® technology, developed by the visionary scientists who discovered the value of FeNO (fractional exhaled nitric oxide) testing in asthma, has played a pivotal role in helping to transform the way asthma can be diagnosed and managed.1-4 FeNO testing has become an important tool for healthcare professionals in assessing airway inflammation and guiding treatment decisions.4-7 The milestone achievement of nearly 50 million FeNO tests performed using NIOX® technology is testament to its widespread adoption and impact on patient health.

In recognition of its commitment to innovation, NIOX® has received prestigious accolades. In 2021, the company was honoured with the award for Most Innovative Asthma Management Technology, highlighting its pioneering contributions to the field. In 2022, NIOX® was named Best FeNO Testing Provider and acknowledged as Leaders in FeNO Testing Technology Development later that same year. These awards not only reflect the dedication of the entire team at NIOX® but also validate the confidence placed in the company by healthcare professionals worldwide.

NIOX® Executive Chairman, Ian Johnson, said: “On this momentous occasion, we would like to express our sincere gratitude to our colleagues and to our customers for their continued support. The success of the past 25 years would not have been possible without the dedication and hard work of the talented individuals who have been part of the NIOX® family. Their commitment to advancing asthma care has been instrumental in shaping the company’s success. Thank you all.”

NIOX® remains committed to driving innovation in asthma management and improving the lives of patients. As the company looks to the future, it continues to invest in research and development to further enhance NIOX® technology. With a continued focus on delivering market-leading products and unparalleled support to healthcare professionals, NIOX® aims to further solidify its position as a global leader in FeNO testing.

Watch the fascinating story of FeNO testing in a new short film:

SourceNIOX® Group

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

0
Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

0
Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

0
EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

0
The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

0
Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

About us

Medical Device News Magazine

Welcome to Medical Device News Magazine, a digital publication providing up to the minute medical device and biotechnology news.

Need to know more?

Contact us

Navigation

Florida, New York, No. Carolina
United States
Phone Number: 1.561.316.3330